MA50580A - Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23 - Google Patents
Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23Info
- Publication number
- MA50580A MA50580A MA050580A MA50580A MA50580A MA 50580 A MA50580 A MA 50580A MA 050580 A MA050580 A MA 050580A MA 50580 A MA50580 A MA 50580A MA 50580 A MA50580 A MA 50580A
- Authority
- MA
- Morocco
- Prior art keywords
- safe
- specific antibody
- effective method
- antibody anti
- psoriasic arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762581996P | 2017-11-06 | 2017-11-06 | |
US201862744386P | 2018-10-11 | 2018-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50580A true MA50580A (fr) | 2020-09-16 |
Family
ID=66326843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050580A MA50580A (fr) | 2017-11-06 | 2018-11-06 | Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190135910A1 (fr) |
EP (1) | EP3706794A4 (fr) |
JP (2) | JP2021502349A (fr) |
KR (1) | KR20200076731A (fr) |
AU (1) | AU2018360789A1 (fr) |
CA (1) | CA3081343A1 (fr) |
IL (1) | IL274272A (fr) |
MA (1) | MA50580A (fr) |
MX (1) | MX2020004716A (fr) |
WO (1) | WO2019090329A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021023295A2 (pt) * | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
MA56124A (fr) * | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
WO2022013745A1 (fr) * | 2020-07-13 | 2022-01-20 | Janssen Biotech, Inc. | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
JP2024510588A (ja) * | 2021-03-12 | 2024-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法 |
US20220298236A1 (en) * | 2021-03-12 | 2022-09-22 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
US20230374122A1 (en) * | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010291927A1 (en) * | 2009-09-14 | 2012-04-12 | AbbVie Deutschland GmbH & Co. KG | Methods for treating psoriasis |
EP2866833B1 (fr) * | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Anticorps il-23 anti-humains cristallins |
WO2015119841A1 (fr) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Rôle de l'il-23 et du pd-1 dans une réponse immunitaire autoréactive |
BR112018069776A2 (pt) * | 2016-03-29 | 2019-02-05 | Janssen Biotech Inc | tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23 |
WO2017180821A1 (fr) * | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Méthodes de traitement de maladies inflammatoires |
AU2017362222A1 (en) * | 2016-11-16 | 2019-05-30 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL-23 specific antibody |
-
2018
- 2018-11-06 AU AU2018360789A patent/AU2018360789A1/en active Pending
- 2018-11-06 EP EP18873516.1A patent/EP3706794A4/fr active Pending
- 2018-11-06 CA CA3081343A patent/CA3081343A1/fr active Pending
- 2018-11-06 US US16/181,733 patent/US20190135910A1/en not_active Abandoned
- 2018-11-06 KR KR1020207015671A patent/KR20200076731A/ko not_active Application Discontinuation
- 2018-11-06 JP JP2020524583A patent/JP2021502349A/ja not_active Withdrawn
- 2018-11-06 MX MX2020004716A patent/MX2020004716A/es unknown
- 2018-11-06 WO PCT/US2018/059444 patent/WO2019090329A1/fr unknown
- 2018-11-06 MA MA050580A patent/MA50580A/fr unknown
-
2020
- 2020-04-27 IL IL274272A patent/IL274272A/en unknown
-
2021
- 2021-07-26 US US17/385,284 patent/US20210363235A1/en active Pending
-
2023
- 2023-09-25 JP JP2023160219A patent/JP2023182641A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021502349A (ja) | 2021-01-28 |
EP3706794A4 (fr) | 2021-08-11 |
MX2020004716A (es) | 2020-11-06 |
US20210363235A1 (en) | 2021-11-25 |
WO2019090329A1 (fr) | 2019-05-09 |
KR20200076731A (ko) | 2020-06-29 |
JP2023182641A (ja) | 2023-12-26 |
IL274272A (en) | 2020-06-30 |
EP3706794A1 (fr) | 2020-09-16 |
CA3081343A1 (fr) | 2019-05-09 |
US20190135910A1 (en) | 2019-05-09 |
AU2018360789A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50580A (fr) | Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23 | |
MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
GB202011417D0 (en) | Machine learning to integrate knowledge and natural language processing | |
MA47220A (fr) | Recherche dynamique et récupération de questions | |
GB2571049B (en) | Method and system for search pattern oblivious dynamic symmetric searchable encryption | |
MA40498A (fr) | Méthode de traitement de l'intoxication par organophosphates | |
MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
MA51899A (fr) | Inhibiteurs de btk et de leurs mutants | |
IL261859B (en) | A method for the treatment of eczema with an increased interval dose of an anti-il12/23 antibody | |
MA46861A (fr) | Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique | |
IL265666A (en) | A safe and effective method for the treatment of eczema with a specific anti-il23 antibody | |
MA42657A (fr) | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines | |
FR3027672B1 (fr) | Methode et dispositifs de traitement d'echantillons biologiques | |
MA56124A (fr) | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 | |
MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
MA43867A (fr) | Appareil de mélange et de traitement et méthode | |
IL281014A (en) | Detection and documentation of speeding violations | |
MA50666A (fr) | Méthode sûre et efficace de traitement de lupus avec un anticorps anti-il12/il23 | |
MA45997A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
FR3056251B1 (fr) | Carter d'echappement renforce et procede de fabrication | |
FR3015356B1 (fr) | Procede de traitement de surface d'un document de securite et document de securite associe | |
MA51295A (fr) | Dosage, procédé et traitement d'alpha-synucléinopathies | |
MA43716A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
CL2016000999A1 (es) | Anticuerpos anti-cd38 específicos para tratar cánceres humanos | |
SG11202105320YA (en) | Methods of treating disease with magl inhibitors |